Beth R Jacobson has filed a suit against Celgene. The lawsuit claims of misappropriation of an idea and unjust enrichment regarding the company’s sale of thalidomide (Thalomid and Revlimid) for the treatment of multiple myeloma.
The suit alleges that Ms Jacobson developed the original and novel idea for treating multiple myeloma with thalidomide and is therefore entitled to compensation consistent with established legal
precedent. Ms Jacobson is represented in this suit by Goodwin Procter.
The suit, which was filed in the US District Court in Newark, New Jersey, seeks a minimum of $300m as past damages and 25% of the future profits resulting from the sale of Celgene’s thalidomide products for the treatment of multiple myeloma.